Physicochemical and anti-bacterial performance characterization of clarithromycin nanoparticles as colloidal drug delivery system

Pinto-Alphandary, 2000, Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications, Int. J. Antimicrob. Agents, 13, 155, 10.1016/S0924-8579(99)00121-1

Fattal, 2000, Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles, Antimicrob. Agents Chemother., 33, 1540, 10.1128/AAC.33.9.1540

Ranjan, 2009, Antibacterial efficacy of core–shell nanostructures encapsulating gentamicin against an in vivo intracellular Salmonella model, Int. J. Nanomed., 4, 289, 10.2147/IJN.S7137

Fawaz, 1998, Ciprofloxacin-loaded polyisobutylcyanoacrylate nanoparticles: pharmacokinetics and in vitro antimicrobial activity, Int. J. Pharm., 168, 255, 10.1016/S0378-5173(98)00116-1

Turos, 2007, Penicillin-bound polyacrylate nanoparticles: restoring the activity of beta-lactam antibiotics against MRSA, Bioorg. Med. Chem. Lett., 17, 3468, 10.1016/j.bmcl.2007.03.077

Soppimath, 2001, Biodegradable polymeric nanoparticles as drug delivery devices, J. Control Release, 70, 1, 10.1016/S0168-3659(00)00339-4

Sharma, 2004, Chemotherapeutic efficacy of poly (d,l-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis, Int. J. Antimicrob. Agents, 24, 599, 10.1016/j.ijantimicag.2004.07.010

Ordonez-Gutierrez, 2007, In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum, Int. J. Antimicrob. Agents, 30, 325, 10.1016/j.ijantimicag.2007.05.013

Deurenberg, 2008, The evolution of Staphylococcus aureus, Infect. Genet. Evol., 8, 747, 10.1016/j.meegid.2008.07.007

Saadatian-Elahi, 2008, Staphylococcus aureus, the major pathogen in orthopaedic and cardiac surgical site infections: a literature review, Int. J. Surg., 6, 238, 10.1016/j.ijsu.2007.05.001

Piscitelli, 1992, Clarithromycin and azithromycin: new macrolide antibiotics, Clin. Pharm., 11, 137

Ramteke, 2009, Amoxicillin, clarithromycin, and omeprazole based targeted nanoparticles for the treatment of H. pylori, J. Drug Target., 17, 225, 10.1080/10611860902718649

Ramteke, 2008, Clarithromycin- and omeprazole-containing gliadin nanoparticles for the treatment of Helicobacter pylori, J. Drug Target., 16, 65, 10.1080/10611860701733278

Adibkia, 2007, Piroxicam nanoparticles for ocular delivery: physicochemical characterization and implementation in endotoxin-induced uveitis, J. Drug Target., 15, 407, 10.1080/10611860701453125

Salem, 2003, Efficacies of cyclodextrin-complexed and liposome-encapsulated clarithromycin against Mycobacterium avium complex infection in human macrophages, Int. J. Pharm., 250, 403, 10.1016/S0378-5173(02)00552-5

Zakeri-Milani, 2009, Pharmacokinetics and comparative bioavailability study of two clarithromycin suspensions following single oral dose to healthy volunteers, Drug Res. (ArzneimForsch), 59, 429

Adibkia, 2007, Inhibition of endotoxin-induced uveitis by methylprednisolone acetate nanosuspension in rabbits, J. Ocul. Pharmacol. Ther., 23, 421, 10.1089/jop.2007.0039

2000

Corrigan, 2009, Quantifying drug release from PLGA nanoparticulates, Eur. J. Pharm. Sci., 37, 477, 10.1016/j.ejps.2009.04.004

Valizadeh, 2004, Physicochemical characterization of solid dispersions of indomethacin with PEG 6000, Myrj 52, lactose, sorbitol, dextrin, and eudragit-E100, Drug Dev. Ind. Pharm., 30, 303, 10.1081/DDC-120030426

Lu, 2007, Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle, J. Control Release, 118, 38, 10.1016/j.jconrel.2006.11.015

Miura, 2004, Antitumor characteristics of methoxypolyethylene glycol–poly(d,l-lactic acid) nanoparticles containing camptothecin, J. Control Release, 97, 101, 10.1016/j.jconrel.2004.03.009

Ahsan, 2002, Targeting to macrophages: role of physicochemical properties of particulate carriers – liposomes and microspheres – on the phagocytosis by macrophages, J. Control Release, 79, 29, 10.1016/S0168-3659(01)00549-1

Sohn, 2000, Polymorphism of clarithromycin, Arch. Pharm. Res., 23, 381, 10.1007/BF02975451

Inoue, 2007, Application of ascorbic acid 2-glucoside as a solubilizing agent for clarithromycin: solubilization and nanoparticle formation, Int. J. Pharm., 331, 38, 10.1016/j.ijpharm.2006.09.014

Bandi, 2004, Preparation of budesonide- and indomethacin-hydroxypropyl-[beta]-cyclodextrin (HPBCD) complexes using a single-step, organic-solvent-free supercritical fluid process, Eur. J. Pharm. Sci., 23, 159, 10.1016/j.ejps.2004.06.007

Valizadeh, 2007, Preparation and characterization of solid dispersions of piroxicam with hydrophilic carriers, Drug Dev. Ind. Pharm., 33, 1, 10.1080/03639040600814965

Fonseca, 2002, Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity, J. Control Release, 83, 273, 10.1016/S0168-3659(02)00212-2

Ahlin, 2002, Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration, Int. J. Pharm., 239, 113, 10.1016/S0378-5173(02)00076-5

Vyas, 2006, Optimizing efficacy of amphotericin B through nanomodification, Int. J. Nanomed., 1, 417, 10.2147/nano.2006.1.4.417

Mohammadi, 2010, Development of azithromycin–PLGA nanoparticles: physicochemical characterization and antibacterial effect against Salmonella typhi, Colloids Surf. B: Biointerfaces, 80, 34, 10.1016/j.colsurfb.2010.05.027

Dillen, 2008, Adhesion of PLGA or Eudragit((R))/PLGA nanoparticles to Staphylococcus and Pseudomonas, Int. J. Pharm., 349, 234, 10.1016/j.ijpharm.2007.07.041